Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2020 | SAUL analysis: atezolizumab in urothelial carcinoma patients

Cora Sternberg • 13 Feb 2020
GU Cancers 2020
Bladder Cancer Genitourinary Cancer Atezolizumab
SAUL

Cora Sternberg, MD, FACP, Weill Cornell Medicine, New York, NY, discusses the subgroup analysis of the single-arm international SAUL study (NCT02928406) in pretreated locally advanced urinary tract carcinoma. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

More from Cora Sternberg

7:53
Growing treatment landscape for advanced bladder cancer
Cora Sternberg • 13 Feb 2020

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals